IRLAB Competitors

Stocks . Sweden . 
Stock . IRLAB Therapeutics AB
IRLAB-A Stock  SEK 1.59  -0.01  -0.63%   
The company operates in Healthcare space and is part of Biotechnology industry. IRLAB Therapeutics competes with Bio Works, Isofol Medical, Annexin Pharmaceuticals, and Karolinska Development and other related companies. This provides context for comparative analysis. Peer comparison for IRLAB Therapeutics provides quick context before deeper valuation work.

IRLAB Therapeutics vs Clinical Laserthermia Correlation Overview

Modest diversification

Across the chosen horizon, IRLAB-A and CLS-B show a correlation of 0.23 and fall into the Modest diversification bucket. Used correctly, the chart helps investors judge whether adding the second position genuinely diversifies the first.

Moving together with IRLAB Stock

  0.83VITR Vitrolife ABPairCorr

Moving against IRLAB Stock

  0.83TELLUS Tellusgruppen ABPairCorr
  0.76DMYD-B Diamyd Medical ABPairCorr
  0.718TRA Traton SEPairCorr
  0.37FLEXQ FlexQube ABPairCorr
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of IRLAB Therapeutics' price to converge to an average value over time is called mean reversion.
Hype
Prediction
LowEstimatedHigh
0.081.594.98
Details
Intrinsic
Valuation
LowRealHigh
0.071.484.87
Details
Naive
Forecast
LowNextHigh
0.031.434.82
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
1.521.701.87
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as IRLAB Therapeutics. Your research has to be compared to or analyzed against IRLAB Therapeutics' peers to derive any actionable benefits.

IRLAB Therapeutics Competition Correlation Matrix

Correlation analysis between IRLAB Therapeutics AB and its competitors helps investors understand whether diversification is real or only superficial inside the same peer group. This matrix is most informative when investors want to know whether adding another peer would improve diversification, increase crowding, or leave total risk largely unchanged.

High positive correlations

ANNX
+ 0.79
IRLAB-A
ALZ
+ 0.78
ANNX
ALZ
+ 0.73
IRLAB-A
ALZ
+ 0.59
KDEV
KDEV
+ 0.57
ANNX
KDEV
+ 0.47
IRLAB-A
  

High negative correlations

ALZ
- 0.8
BIOWKS
ANNX
- 0.62
BIOWKS
IRLAB-A
- 0.59
BIOWKS
KDEV
- 0.55
BIOWKS
CLS-B
- 0.29
ISOFOL
ISOFOL
- 0.29
BIOWKS

Risk-Adjusted Indicators

There is a big difference between IRLAB Stock performing well and IRLAB Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze IRLAB Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

IRLAB Therapeutics Competitive Analysis

The better you understand IRLAB Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, IRLAB Therapeutics' competitive analysis can cover a whole range of metrics.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
IRLAB-A BIOWKS ISOFOL ANNX KDEV ALZ CLS-B
 0.63 
1.59
IRLAB
 2.84 
3.08
Bio
 2.99 
0.69
Isofol
 0.69 
14.40
Annexin
 0.00 
0.29
Karolinska
 1.72 
0.57
Alzinova
 3.02 
5.45
Clinical
Market Volatility
(90 Days Market Risk)
Very High
Very High
Stable
Slightly Elevated
Stable
Stable
Elevated
Market Performance
(90 Days Performance)
Weak
Moderate
Soft
Weak
Weak
Weak
Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Moderate
High
High
High
Fair
Fair
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Fairly Valued
Fairly Valued
Over Valued
Over Valued
Buy or Sell Analysis
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Current Ratio
9.19 X
9.14 X
1.21 X
9.56 X
0.24 X
N/A
3.61 X
Net Asset
472.45 M
120.86 M
401.36 M
52.79 M
1.11 B
91.69 M
66.74 M
Profit Margin
-1.69 %
-1.31 %
N/A
N/A
N/A
-0.68 %
N/A
EBITDA
55.62 M
-8.6 M
-198.49 M
-50.28 M
177.79 M
-7.52 M
-54.42 M
Operating Margin
-1.68 %
-1.27 %
-13.09 %
N/A
-14.44 %
-0.68 %
-23.95 %
Current Valuation
1.74 B
635.01 M
-42.41 M
125.48 M
247.24 M
16.38 M
73.29 M
Price To Book
6.24 X
8.03 X
0.65 X
4.90 X
0.37 X
0.39 X
4.26 X
Retained Earnings
N/A
N/A
N/A
N/A
-1.85 B
-1000 K
-88 M
Current Asset
N/A
N/A
N/A
N/A
259 M
N/A
22 M
Beta
0.16
0.99
1.56
1.55
0.4
1.06
0.78
Number Of Employees
31
36
15
4
7
3
12
Shares Outstanding
51.79 M
34.87 M
161.52 M
154.5 M
267.28 M
32.42 M
134.52 M
Cash Flow From Operations
128.64 M
-13.37 M
-188.43 M
-45.02 M
16.7 M
-9.82 M
-66.17 M
Total Debt
3.57 M
N/A
110 K
N/A
N/A
N/A
100 K
Return On Equity
-0.28
-0.66
-0.69
-1.06
-0.11
-0.11
-2.59
Z Score
88.2
N/A
N/A
N/A
-1.4
N/A
N/A
Return On Asset
-0.15
-0.35
-0.36
-0.57
-0.0168
-0.0645
-0.66
Book Value Per Share
6.25 X
2.55 X
1.14 X
0.20 X
4.56 X
3.40 X
0.18 X
Current Liabilities
N/A
N/A
N/A
N/A
9 M
N/A
8 M
Total Asset
472.45 M
120.86 M
401.36 M
52.79 M
1.11 B
91.69 M
66.74 M
Debt To Equity
2.90 %
N/A
0.05 %
1.20 %
177.80 %
N/A
3.20 %
Target Price
200.0
27.0
1.31
2.0
4.5
19.69
1.4
Shares Owned By Institutions
22.49 %
5.59 %
12.47 %
5.06 %
5.97 %
0.90 %
2.27 %
Market Capitalization
525.71 M
718.4 M
109.18 M
189.95 M
510.26 M
139 M
104.76 M
Price To Earning
N/A
N/A
N/A
N/A
7.42 X
N/A
-10.13 X
Price To Sales
33.49 X
19.71 X
7.45 X
N/A
204.26 X
6.64 X
28.92 X
Net Income
51.78 M
-12.94 M
-200.25 M
-52.14 M
170.82 M
-7.55 M
-63.62 M
Earnings Per Share
0.81 X
-0.41 X
-1.42 X
-0.43 X
0.86 X
-0.53 X
-1.08 X
Shares Owned By Insiders
38.63 %
54.85 %
25.71 %
45.17 %
37.17 %
19.76 %
9.70 %
Revenue
207.78 M
21.91 M
22.41 M
N/A
2.17 M
N/A
2.25 M
Working Capital
N/A
N/A
N/A
N/A
250 M
N/A
14 M
Cash And Equivalents
401.9 M
46.35 M
379.45 M
22.77 M
42.4 M
N/A
13.5 M
Cash Per Share
2.89 X
2.40 X
0.93 X
1.29 X
1.85 X
N/A
0.39 X
Gross Profit
126.05 M
53.01 M
-174.31 M
N/A
2.17 M
17.32 M
-3.63 M
Day Typical Price
1.57
3.02
0.68
14.27
0.29
0.58
5.35
Accumulation Distribution
15796.57
18393.91
17092.41
98.11
N/A
45426.89
13012.61
Market Facilitation Index
N/A
0.0
N/A
1.0E-4
N/A
N/A
0.0
Daily Balance Of Power
-0.11
-0.24
1.0
-0.25
0.0
-0.25
-0.29
Period Momentum Indicator
-0.01
-0.09
0.02
-0.10
N/A
-0.01
-0.17
Rate Of Daily Change
0.99
0.97
1.03
0.99
1.0
0.98
0.97
Day Median Price
1.57
2.99
0.68
14.2
0.29
0.59
5.3
Price Action Indicator
0.02
0.045
0.02
0.15
N/A
-0.03
0.07
Relative Strength Index
39.89
57.01
50.41
42.1
47.19
16.29
40.12
Coefficient Of Variation
-1,091
901.88
83214.58
-1,180
-807.80
-448.59
-25,586
Mean Deviation
2.7
2.96
2.77
4.18
4.52
2.81
3.88
Jensen Alpha
-0.34
0.4235
-0.0032
-0.57
-1.06
-1.39
-0.04
Total Risk Alpha
-0.34
0.4251
-0.0015
-0.57
-1.06
-1.39
-0.04
Sortino Ratio
N/A
0.1307
-0.0008
N/A
N/A
N/A
N/A
Downside Variance
N/A
10.53
14.09
N/A
N/A
N/A
N/A
Standard Deviation
3.62
3.91
5.56
6.61
8.47
6.18
7.2
Kurtosis
0.4602
1.22
31.79
10.05
12.38
34.29
16.03
Potential Upside
6.51
8.89
2.99
9.04
11.54
4.0
7.51
Treynor Ratio
0.5567
-0.39
-0.01
3.02
1.19
9.8
-0.03
Maximum Drawdown
18.07
16.66
50.92
44.62
47.86
54.47
51.78
Variance
13.11
15.31
30.9
43.66
71.74
38.16
51.84
Market Risk Adjusted Performance
0.5667
-0.38
0.0044
3.03
1.2
9.81
-0.02
Risk Adjusted Performance
-0.06
0.0941
0.0095
-0.06
-0.09
-0.16
0.0059
Skewness
0.0875
0.972
4.57
2.14
-1.01
-4.95
-1.56
Semi Deviation
N/A
2.74
3.13
N/A
N/A
N/A
N/A
Information Ratio
-0.09
0.1084
-0.0006
-0.09
-0.12
-0.22
-0.01
Value At Risk
-6.47
-4.50
-4.17
-8.94
-13.16
-5.63
-7.38
Expected Short fall
N/A
-3.69
-4.16
N/A
N/A
N/A
N/A
Downside Deviation
N/A
3.24
3.75
N/A
N/A
N/A
N/A
Semi Variance
N/A
7.53
9.82
N/A
N/A
N/A
N/A

IRLAB Therapeutics Peer Performance Charts

How to Analyze IRLAB Therapeutics Against Peers

IRLAB Therapeutics' peer analysis compares IRLAB Therapeutics with related companies to put valuation, quality, and risk metrics in context. This helps determine whether recent performance is company-specific or broadly sector-driven. A practical workflow includes:
  • Set a relevant peer group: Include direct competitors and close alternatives with comparable business exposure.
  • Benchmark core financials: Compare profitability, growth, capital structure, and cash flow quality.
  • Check valuation dispersion: Review whether IRLAB Therapeutics trades at a premium or discount versus peers and why.
  • Evaluate risk profile: Compare volatility, drawdowns, and correlation to avoid false diversification assumptions.
  • Document the thesis: Record where IRLAB Therapeutics leads or lags and what catalysts could close or widen the gap.
Use this as an educational baseline, then validate conclusions with current filings, market conditions, and portfolio objectives.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY